At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09688 ZAI LAB
Not Yet Opened 11-13 16:08:17
20.240
-0.780
-3.71%
High20.820
Low20.020
Vol3.44M
Open20.820
D1 Closing21.020
Amplitude3.81%
Mkt Cap25.46B
Tradable Cap25.46B
Total Shares1.26B
T/O69.67M
T/O Rate0.27%
Tradable Shares1.26B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Zai Lab Announces Participation in UBS and Jefferies Investor Conferences
Zai Lab Posts 3Q 2026 Net Loss of USD 46.14 Million as Product Sales Dip 7%; Cash on Hand at USD 659.66 Million Ahead of USD 241.20 Million Private Placement Inflow
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.